Bioxytran, Inc. (OTCMKTS:BIXT) Sees Significant Decline in Short Interest

Bioxytran, Inc. (OTCMKTS:BIXT) saw a significant decline in short interest in February. As of February 13th, there was short interest totaling 409 shares, a decline of 92.8% from the January 29th total of 5,695 shares. Based on an average trading volume of 393,057 shares, the short-interest ratio is presently 0.0 days. Approximately 0.0% of the shares of the stock are short sold. Approximately 0.0% of the shares of the stock are short sold. Based on an average trading volume of 393,057 shares, the short-interest ratio is presently 0.0 days.

Bioxytran Price Performance

OTCMKTS BIXT traded up $0.00 on Wednesday, reaching $0.04. 366,794 shares of the company’s stock traded hands, compared to its average volume of 208,370. The stock has a 50-day simple moving average of $0.06 and a 200 day simple moving average of $0.07. Bioxytran has a 12 month low of $0.03 and a 12 month high of $0.23. The stock has a market cap of $4.81 million, a PE ratio of -1.42 and a beta of 1.99.

About Bioxytran

Bioxytran, Inc is a clinical-stage biotechnology company focused on the development of synthetic oxygen carriers and novel oxygen therapeutics for acute care and chronic disease applications. The company’s proprietary platform is designed to safely deliver therapeutic levels of oxygen to hypoxic tissues, addressing conditions such as ischemia-reperfusion injury, organ transplantation, and traumatic injury. Its lead product candidates target unmet medical needs in cardiovascular and neurological disorders, wound healing, and critical care settings.

Bioxytran’s research pipeline comprises multiple preclinical-stage assets that leverage stabilized perfluorocarbon emulsions to achieve controlled oxygen release.